Keith Tan

BioPharmaceuticals R&D
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer's Disease clinical trial.

AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer's Disease clinical trial.

Journal: Nature communications
Published: December 08, 2024

MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non-clinical species and Alzheimer's disease patients.

MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non-clinical species and Alzheimer's disease patients.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: April 03, 2024

StarGazer: A Hybrid Intelligence Platform for Drug Target Prioritization and Digital Drug Repositioning Using Streamlit.

StarGazer: A Hybrid Intelligence Platform for Drug Target Prioritization and Digital Drug Repositioning Using Streamlit.

Journal: Frontiers in genetics
Published: February 01, 2022

Compounds activating VCP D1 ATPase enhance both autophagic and proteasomal neurotoxic protein clearance.

Compounds activating VCP D1 ATPase enhance both autophagic and proteasomal neurotoxic protein clearance.

Journal: Nature communications
Published: October 11, 2021

VCP/p97 regulates Beclin-1-dependent autophagy initiation.

VCP/p97 regulates Beclin-1-dependent autophagy initiation.

Journal: Nature chemical biology
Published: August 20, 2019

Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo.

Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo.

Journal: Neurobiology of disease
Published: July 19, 2019

Biomarker of extracellular matrix remodelling C1M and proinflammatory cytokine interleukin 6 are related to synovitis and pain in end-stage knee osteoarthritis patients.

Biomarker of extracellular matrix remodelling C1M and proinflammatory cytokine interleukin 6 are related to synovitis and pain in end-stage knee osteoarthritis patients.

Journal: Pain
Published: March 24, 2017

Molecular-based diagnosis of multiple sclerosis and its progressive stage.

Molecular-based diagnosis of multiple sclerosis and its progressive stage.

Journal: Annals of neurology
Published: February 04, 2017

Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies.

Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies.

Journal: Journal of Alzheimer's disease : JAD
Published: September 25, 2015
Showing 1-9 of 9

Last Updated: 09/26/2026